Evotec SE reported €797M of revenue over the trailing twelve months, +2.0% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €797M (to FY2024). Net income: −€196M, trailing twelve months to FY2024. Free cash flow: −€99M, trailing twelve months to FY2024. Operating margin: −18%, trailing twelve months to FY2024.

EVOEvotec SE

Healthcare

$1.57-61% 1Y

$1.57

$1.5352 weeks$4.15

EVO as reported

Evotec SE reported €797M of revenue over the trailing twelve months, +2.0% on the year before. 10 reported series are charted on this page, each one as filed.

€797M

Revenue, trailing twelve months · to FY2024 · +2.0% against the twelve months before

Net income: −€196M
Net income · +134% year on year · trailing twelve months to FY2024
Free cash flow: −€99M
Free cash flow · −44% year on year · trailing twelve months to FY2024
Operating margin: −18%
Operating margin · trailing twelve months to FY2024

Details›

Every series Ryufin has for EVO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€797M	+2.0%	FY2024
Net income	−€196M	+134%	FY2024
EPS	−€1.11	+136%	FY2024
Gross margin	14%	n/a	FY2024
Operating margin	−18%	n/a	FY2024
Net margin	−25%	n/a	FY2024
ROE	−21%	n/a	FY2024
ROA	−10%	n/a	FY2024
ROIC	−12%	n/a	FY2024
Free cash flow	−€99M	−44%	FY2024

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.